Diagnosis and Treatment of Neurocysticercosis: 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH)

A. Clinton White, Christina M. Coyle, Vedantam Rajshekhar, Gagandeep Singh, W. Allen Hauser, Aaron Mohanty, Hector H. Garcia, Theodore E. Nash

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Gidelines for the clinical management of patients with neurocysticercosis (NCC) were prepared by a panel of the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). The guidelines are intended for infectious disease specialists, neurologists, neurological surgeons, internists, pediatricians, and family practitioners. These guidelines present our approaches to the diagnosis and management of patients with the different forms of neurocysticercosis,including viable parenchymal neurocysticercosis,single enhancing lesions, calcified parenchymal neurocysticercosis,ventricular neurocysticercosis, and subarachnoid neurocysticercosis. Our recommendations are based on the best evidence available. Due to the complex variations in clinical manifestations and the limitations of the literature, many of the recommendations are based on observational studies, anecdotal data, or expert opinion rather than randomized clinical trials. The approaches we describe are intended to be both applicable and feasible in the United States and Canada (for simplicity, referred to here as North America). The recommendations may not apply for settings where resource constraints may limit their applicability. The executive summary below lists the recommendations for the diagnosis and clinical management of neurocysticercosis. A detailed description of the methods, background, and evidence summaries that support each of the recommendations can be found online in the full text of the guidelines. A criterion for grading evidence is presented in Figure 1 [1]. Note that diagnosis and management of patients with neurocysticercosis can be challenging even with expert guidelines. Due to this complexity, clinicians with little experience with this disease should have a low threshold for consultation with an expert in the disease.

Original languageEnglish (US)
Pages (from-to)1159-1163
Number of pages5
JournalClinical Infectious Diseases
Volume66
Issue number8
DOIs
StatePublished - Apr 3 2018

Fingerprint

Neurocysticercosis
Practice Guidelines
Guidelines
Therapeutics
Expert Testimony
North America
Canada
Observational Studies
Communicable Diseases
Referral and Consultation
Randomized Controlled Trials

Keywords

  • cysticercosis
  • neurocysticersosis
  • Taenia solium
  • taeniasis

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Diagnosis and Treatment of Neurocysticercosis : 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). / White, A. Clinton; Coyle, Christina M.; Rajshekhar, Vedantam; Singh, Gagandeep; Hauser, W. Allen; Mohanty, Aaron; Garcia, Hector H.; Nash, Theodore E.

In: Clinical Infectious Diseases, Vol. 66, No. 8, 03.04.2018, p. 1159-1163.

Research output: Contribution to journalReview article

@article{e78e8363877d43cd9cfeb89e1a5be704,
title = "Diagnosis and Treatment of Neurocysticercosis: 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH)",
abstract = "Gidelines for the clinical management of patients with neurocysticercosis (NCC) were prepared by a panel of the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). The guidelines are intended for infectious disease specialists, neurologists, neurological surgeons, internists, pediatricians, and family practitioners. These guidelines present our approaches to the diagnosis and management of patients with the different forms of neurocysticercosis,including viable parenchymal neurocysticercosis,single enhancing lesions, calcified parenchymal neurocysticercosis,ventricular neurocysticercosis, and subarachnoid neurocysticercosis. Our recommendations are based on the best evidence available. Due to the complex variations in clinical manifestations and the limitations of the literature, many of the recommendations are based on observational studies, anecdotal data, or expert opinion rather than randomized clinical trials. The approaches we describe are intended to be both applicable and feasible in the United States and Canada (for simplicity, referred to here as North America). The recommendations may not apply for settings where resource constraints may limit their applicability. The executive summary below lists the recommendations for the diagnosis and clinical management of neurocysticercosis. A detailed description of the methods, background, and evidence summaries that support each of the recommendations can be found online in the full text of the guidelines. A criterion for grading evidence is presented in Figure 1 [1]. Note that diagnosis and management of patients with neurocysticercosis can be challenging even with expert guidelines. Due to this complexity, clinicians with little experience with this disease should have a low threshold for consultation with an expert in the disease.",
keywords = "cysticercosis, neurocysticersosis, Taenia solium, taeniasis",
author = "White, {A. Clinton} and Coyle, {Christina M.} and Vedantam Rajshekhar and Gagandeep Singh and Hauser, {W. Allen} and Aaron Mohanty and Garcia, {Hector H.} and Nash, {Theodore E.}",
year = "2018",
month = "4",
day = "3",
doi = "10.1093/cid/ciy157",
language = "English (US)",
volume = "66",
pages = "1159--1163",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Diagnosis and Treatment of Neurocysticercosis

T2 - 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH)

AU - White, A. Clinton

AU - Coyle, Christina M.

AU - Rajshekhar, Vedantam

AU - Singh, Gagandeep

AU - Hauser, W. Allen

AU - Mohanty, Aaron

AU - Garcia, Hector H.

AU - Nash, Theodore E.

PY - 2018/4/3

Y1 - 2018/4/3

N2 - Gidelines for the clinical management of patients with neurocysticercosis (NCC) were prepared by a panel of the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). The guidelines are intended for infectious disease specialists, neurologists, neurological surgeons, internists, pediatricians, and family practitioners. These guidelines present our approaches to the diagnosis and management of patients with the different forms of neurocysticercosis,including viable parenchymal neurocysticercosis,single enhancing lesions, calcified parenchymal neurocysticercosis,ventricular neurocysticercosis, and subarachnoid neurocysticercosis. Our recommendations are based on the best evidence available. Due to the complex variations in clinical manifestations and the limitations of the literature, many of the recommendations are based on observational studies, anecdotal data, or expert opinion rather than randomized clinical trials. The approaches we describe are intended to be both applicable and feasible in the United States and Canada (for simplicity, referred to here as North America). The recommendations may not apply for settings where resource constraints may limit their applicability. The executive summary below lists the recommendations for the diagnosis and clinical management of neurocysticercosis. A detailed description of the methods, background, and evidence summaries that support each of the recommendations can be found online in the full text of the guidelines. A criterion for grading evidence is presented in Figure 1 [1]. Note that diagnosis and management of patients with neurocysticercosis can be challenging even with expert guidelines. Due to this complexity, clinicians with little experience with this disease should have a low threshold for consultation with an expert in the disease.

AB - Gidelines for the clinical management of patients with neurocysticercosis (NCC) were prepared by a panel of the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). The guidelines are intended for infectious disease specialists, neurologists, neurological surgeons, internists, pediatricians, and family practitioners. These guidelines present our approaches to the diagnosis and management of patients with the different forms of neurocysticercosis,including viable parenchymal neurocysticercosis,single enhancing lesions, calcified parenchymal neurocysticercosis,ventricular neurocysticercosis, and subarachnoid neurocysticercosis. Our recommendations are based on the best evidence available. Due to the complex variations in clinical manifestations and the limitations of the literature, many of the recommendations are based on observational studies, anecdotal data, or expert opinion rather than randomized clinical trials. The approaches we describe are intended to be both applicable and feasible in the United States and Canada (for simplicity, referred to here as North America). The recommendations may not apply for settings where resource constraints may limit their applicability. The executive summary below lists the recommendations for the diagnosis and clinical management of neurocysticercosis. A detailed description of the methods, background, and evidence summaries that support each of the recommendations can be found online in the full text of the guidelines. A criterion for grading evidence is presented in Figure 1 [1]. Note that diagnosis and management of patients with neurocysticercosis can be challenging even with expert guidelines. Due to this complexity, clinicians with little experience with this disease should have a low threshold for consultation with an expert in the disease.

KW - cysticercosis

KW - neurocysticersosis

KW - Taenia solium

KW - taeniasis

UR - http://www.scopus.com/inward/record.url?scp=85045149899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045149899&partnerID=8YFLogxK

U2 - 10.1093/cid/ciy157

DO - 10.1093/cid/ciy157

M3 - Review article

C2 - 29617787

AN - SCOPUS:85045149899

VL - 66

SP - 1159

EP - 1163

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 8

ER -